MTOR inhibitor-based combination therapies for pancreatic cancer

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

(2017) Vincent Chung et al.   JAMA Oncology

mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer

(2016) David R. Driscoll et al.   CANCER RESEARCH

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer

(2016) J.-Y. Kim et al.   MOLECULAR CANCER RESEARCH

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update

(2016) Enis Afgan et al.   NUCLEIC ACIDS RESEARCH

Heatmapper: web-enabled heat mapping for all

(2016) Sasha Babicki et al.   NUCLEIC ACIDS RESEARCH

Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome

(2016) Goran Hamid Mohammad et al.   PLoS One

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

(2015) C. Garcia-Garcia et al.   CLINICAL CANCER RESEARCH

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling

(2015) Bo Kong et al.   GUT

mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer

(2015) Feng Wei et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The c-Myc–LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer

(2015) Tian-Lin He et al.   MEDICAL ONCOLOGY

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling

(2015) Hee-Bum Kang et al.   MOLECULAR CELL

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

(2015) Tauno Metsalu et al.   NUCLEIC ACIDS RESEARCH

KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells

(2015) S Diersch et al.   ONCOGENE

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

(2015) Anneleen Daemen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors

(2015) S N Payne et al.   Oncogenesis

Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations

(2014) Y. Bai et al.   CANCER RESEARCH

Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

(2014) B. Alagesan et al.   CLINICAL CANCER RESEARCH

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer

(2014) T. Yoshida et al.   CLINICAL CANCER RESEARCH

PI3K Regulation of RAC1 Is Required for KRAS-Induced Pancreatic Tumorigenesis in Mice

(2014) Chia-Yen C. Wu et al.   GASTROENTEROLOGY

Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α

(2014) Romain Baer et al.   GENES & DEVELOPMENT

Targeting mTOR dependency in pancreatic cancer

(2014) Douglas C Morran et al.   GUT

Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance

(2014) E. Rozengurt et al.   MOLECULAR CANCER THERAPEUTICS

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

(2014) M. R. Junttila et al.   MOLECULAR CANCER THERAPEUTICS

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer

(2014) Nina Schönhuber et al.   NATURE MEDICINE

Metabolic regulator LKB1 is crucial for Schwann cell–mediated axon maintenance

(2014) Bogdan Beirowski et al.   NATURE NEUROSCIENCE

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib

(2014) Matthias Wirth et al.   NUCLEIC ACIDS RESEARCH

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

(2013) Kurt G. Pike et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Web-based visual analysis for high-throughput genomics

(2013) Jeremy Goecks et al.   BMC GENOMICS

Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer

(2013) Stefan Eser et al.   CANCER CELL

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

Resolving Molecular Events in the Regulation of Meiosis in Male and Female Germ Cells

(2013) S. Kumar et al.   Science Signaling

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

(2012) S. V. Holt et al.   CANCER RESEARCH

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

(2012) Alan L. Ho et al.   PLoS One

Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages

(2012) K. Clark et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer

(2012) Sarat Chandarlapaty   Cancer Discovery

Novel cross-talk within the IKK family controls innate immunity

(2011) Kristopher Clark et al.   BIOCHEMICAL JOURNAL

Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis

(2011) Alyssa L. Kennedy et al.   MOLECULAR CELL

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

(2010) Milind M Javle et al.   BMC CANCER

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

(2010) I Garrido-Laguna et al.   BRITISH JOURNAL OF CANCER

ROSA26Flpo deleter mice promote efficient inversion of conditional gene traps in vivo

(2010) Christopher S. Raymond et al.   GENESIS

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

(2009) P Cao et al.   BRITISH JOURNAL OF CANCER

E-Cadherin Regulates Metastasis of Pancreatic Cancer In Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex

(2009) Johannes von Burstin et al.   GASTROENTEROLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols